No Time to Die, the 25th James Bond film, has earned an estimated $56 million at the domestic box office in its first weekend and has surpassed $300 million globally.
As reported by THR, No Time to Die secured a box office win over Venom: Let There Be Carnage's $32 million and had the fifth-best domestic opening in the COVID-19 pandemic era.
No Time to Die's domestic box office was a bit under expectations as MGM and EON Productions "had hoped to cross $60 million in its domestic launch based on tracking and advance ticket sales."
The latest Bond film is estimated to cost $250 million - $300 million before marketing, and its run-time of two hours and 43 minutes could have played a part in the ticket sales as it could have limited showtimes. Speaking of run-time, No Time to Die clocks in at the longest in the franchise.
Overseas, No Time to Die earned another $89.5 million from 66 markets, bringing its international total to $257.4 million. Combining with its domestic haul, No Time to Die is sitting at around $313.3 million globally. The film has yet to open in China.
Venom: Let There Be Carnage, which set a pandemic record with its $90 million debut last week, has seen its global total reach $185.6 million.
Marvel's Shang-Chi and the Legend of the Ten Rings has reached $400 million globally and is helping set Disney up to be the first studio to cross $2 billion in 2021 global ticket sales.
Dune, which will finally release in North America on October 22, crossed the $100 million mark internationally with a global total of $117.1 million.
In North America, The Addams Family 2 placed third with $10 million, Shang-Chi followed with $4.2 million, and The Many Saints of Newark rounded out the top five with just $1.5 million.
For more, check out our No Time to Die review, our explainer of the ending, and Daniel Craig's comments on how he hopes that James Bond has "changed a lot" while he's played him.
Have a tip for us? Want to discuss a possible story? Please send an email to [email protected].
Adam Bankhurst is a news writer for IGN. You can follow him on Twitter @AdamBankhurst and on Twitch.
Continue reading...
As reported by THR, No Time to Die secured a box office win over Venom: Let There Be Carnage's $32 million and had the fifth-best domestic opening in the COVID-19 pandemic era.
No Time to Die's domestic box office was a bit under expectations as MGM and EON Productions "had hoped to cross $60 million in its domestic launch based on tracking and advance ticket sales."
The latest Bond film is estimated to cost $250 million - $300 million before marketing, and its run-time of two hours and 43 minutes could have played a part in the ticket sales as it could have limited showtimes. Speaking of run-time, No Time to Die clocks in at the longest in the franchise.
Overseas, No Time to Die earned another $89.5 million from 66 markets, bringing its international total to $257.4 million. Combining with its domestic haul, No Time to Die is sitting at around $313.3 million globally. The film has yet to open in China.
Venom: Let There Be Carnage, which set a pandemic record with its $90 million debut last week, has seen its global total reach $185.6 million.
Marvel's Shang-Chi and the Legend of the Ten Rings has reached $400 million globally and is helping set Disney up to be the first studio to cross $2 billion in 2021 global ticket sales.
Dune, which will finally release in North America on October 22, crossed the $100 million mark internationally with a global total of $117.1 million.
In North America, The Addams Family 2 placed third with $10 million, Shang-Chi followed with $4.2 million, and The Many Saints of Newark rounded out the top five with just $1.5 million.
For more, check out our No Time to Die review, our explainer of the ending, and Daniel Craig's comments on how he hopes that James Bond has "changed a lot" while he's played him.
Have a tip for us? Want to discuss a possible story? Please send an email to [email protected].
Adam Bankhurst is a news writer for IGN. You can follow him on Twitter @AdamBankhurst and on Twitch.
Continue reading...